A Single-Center, Open-Label, Multi-Cycle Study to Evaluate the Pharmacokinetic Profile of Different Doses of ABSK021 Capsules and the Effect of a High-Fat Meal and Omeprazole Enteric-coated Tablets on the Pharmacokinetic Profile of ABSK021 Capsules in Healthy Subjects
Latest Information Update: 25 Feb 2025
At a glance
- Drugs Omeprazole (Primary) ; Pimicotinib (Primary)
- Indications Amyotrophic lateral sclerosis; Graft-versus-host disease; Osteosarcoma; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Abbisko Therapeutics
Most Recent Events
- 18 Feb 2025 Status changed from not yet recruiting to completed.
- 26 Mar 2024 New trial record